Table 1 Clinical characteristics of the study subjects

Age (median, range)

61, 42-81

59, 24-74

0.294

Tumor phenotype

ER/PR positive and HER2 negative

14

19

0.783

HER2 positive

5

5

0.695

Triple negative

2

6

0.277

Unknown

3

0

0.081

Histology

0.384

Ductal

19

26

Lobular

2

0

Others

0

1

Unknown

3

3

Initial clinical stage

I

-

6

II

7

15

III

8

6

IV

8

2

unknown

1

1

Follow-up period (months)

Median (range)

26 (3–58)

40.5 (9–69)